Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children

Journal of Rheumatology

Volumn 33, Issue 12, 2006, Pages 2538-2540

  Roldan, Rosa ^a,b   Morote, Guadalupe ^a   Castro, Maria Del Carmen ^a   Miranda, Maria Dolores ^a   Moreno, Jose Carlos ^a   Collantes, Eduardo ^a  

^a Department of Rheumatology ^*

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Bosentan; Efficacy; Localized scleroderma; Pansclerotic morphea

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; METHOTREXATE; PENICILLAMINE;

ANKLE; ARTICLE; CASE REPORT; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FASCIA; FEMALE; FINGER; HIP; HUMAN; JOINT CONTRACTURE; JOINT MOBILIZATION; KNEE; LIVER TOXICITY; LOCALIZED SCLERODERMA; MORPHEA; MULTIPLE CYCLE TREATMENT; PANSCLEROTIC MORPHEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RARE DISEASE; SKIN FIBROSIS; SKIN ULCER; SKINFOLD THICKNESS; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CHILD, PRESCHOOL; CONTRACTURE; DISABLED CHILDREN; FEMALE; HUMANS; SCLERODERMA, LOCALIZED; SKIN ULCER; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33846108378     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980;116:169-73.
2. Falanga V. Fibrosing conditions in childhood. Adv Dermatol 1991;6:145-58.
3. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190-9.
4. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
5. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
6. Seibold JR, Denton CP, Furst D, et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheum 2005; Suppl 52:4057.
7. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology Oxford 2003;42:191-3.
8. Ramos-Casals M, Brito-Zeron P, Nardi N, et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology Oxford 2004;43:1454-6.
9. Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS. Resolution of severe digital ulceration during a course of bosentan therapy. Ann Intern Med 2005;142:802-3.
10. Nguyen XH, Hansen R, Valencia F. Severe ankle deformity secondary to pansclerotic morphea in a 9-year-old girl: correction involving arthrodesis and free flap coverage. Pediatr Dermatol 2002;19:560-3.
11. Yildirim M, Baysal V, Aridogan BC, Kesici D, Erturan I. Pansclerotic morphea treated with UVA: a case report. J Dermatol 2003;30:625-7.
12. Wollina U, Looks A, Uhlemann C, Wollina K. Pansclerotic morphea of childhood-follow-up over 6 years. Pediatr Dermatol 1999;16:245-7.
13. Scharffetter-Kochanek K, Goldermann R, Lehmann P, Holzle E, Goerz G. PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol 1995;132:830-1.
14. Gruss C, Stucker M, Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol 1997;136:293-4.
15. Todd DJ, Askari A, Ektaish E. PUVA therapy for disabling pansclerotic morphoea of children. Br J Dermatol 1998;138:201-2.
16. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.